Is there a therapeutic future for 'potassium channel openers'?

Clinical Science

Volumn 91, Issue 6, 1996, Pages 651-663

  Lawson, Kim ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

ATP sensitive K channels; Cromakalim; Potassium channel openers; Therapeutic targets

Indexed keywords

ADENOSINE TRIPHOSPHATE; CROMAKALIM; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT;

ANIMAL EXPERIMENT; CELL FUNCTION; ELECTRIC ACTIVITY; ELECTROPHYSIOLOGY; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029804854     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0910651     Document Type: Review

References (111)

1. Hille B. Ionic channels of excitable membranes. Sunderland, MA: Sinauer Associates, 1992.
2. Rudy B. Diversity and ubiquity of K channels. Neuroscience 1988; 25: 729-49.
3. Cook NS. Potassium channels. Structure, classification, function and therapeutic potential. Chichester: Ellis Norwood, 1990.
4. Dreyer F. Peptide toxins and potassium channels. Rev Physiol Biochem Pharmacol 1990; 115: 93-136.
5. Kolb H-A. Potassium channels in excitable and non-excitable cells. Rev Physiol Biochem Pharmacol 1990; 115: 51-91.
6. Robertson DW, Steinberg MI. Potassium channel modulators: scientific applications and therapeutic promise. J Med Chem 1990; 33: 1529-41.
7. Aronson JK. Potassium channels in nervous tissue. Biochem Pharmacol 1992; 43: 11-14.
8. Gopalakrishnan M, Janis RA, Triggle DJ. ATP sensitive K channels: Pharmacologic properties and therapeutic potential. Drug Dev Res 1993; 28: 95-127.
9. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993; 33: 597-637.
10. Hamilton TC, Weston AH. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. Gen Pharmacol 1989; 20: 1-9.
11. Longman SD, Hamilton TC. Potassium channel activator drugs: mechanism of action, pharmacological properties and therapeutic potential. Med Res Rev 1992; 12: 73-148.
12. Edwards G, Weston AH. Pharmacology of the potassium channel openers. Cardiovasc Drugs Ther 1995; 9: 185-93.
13. Laurent F, Michel A, Bonnet PA, Chapat JP, Boucard M. Evaluation of the relaxant effects of SCA40, a novel charybdotoxin-sensitive potassium channel opener, in guinea-pig isolated trachealis. Br J Pharmacol 1993; 108: 622-6.
14. 2+ dependent K channels by novel benzimidazolone. Eur J Pharmacol 1994; 251: 53-9.
15. Atwal KS. Modulation of potassium channels by organic molecules. Med Res Rev 1992; 12: 569-91.
16. Quast U, Bray KM, Baumlin Y, Dosogne J. Potassium channel openers: pharmacology and therapeutic prospects. In: Angelini P, Guilini U, Quaglia W, eds. Trends in receptor research. Amsterdam: Elsevier Science Publishers, 1992: 309-32.
17. Lawson, K, Hicks PE. Potassium channel openers: pharmacological anomalies suggest heterogeneous sites of action. Curr Opin Invest Drugs 1993; 2: 1209-16.
18. Ashcroft SH, Ashcroft FM. Properties and functions of a TP-sensitive K-channels. Cell Signalling 1990; 2: 197-214.
19. + channel. 2. Cloning and distribution of alternative forms. Am J Physiol 1995; 37: F1132-40.
20. 3H] P1075 in rat isolated aorta: relationship to functional effects of openers and blockers. Mol Pharmacol 1993; 43: 474-81.
21. 3H]cromakalim in vascular and bronchial smooth muscle cells. Br J Pharmacol 1992; 107: 396P.
22. + channel openers cromakalim and minoxidil sulphate on vascular smooth muscle. Br J Pharmacol 1991; 103: 1148-52.
23. Lawson K, Barras M, Zazzi-Sudriez E, Martin DJ, Armstrong JM, Hicks PE. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers. Br J Pharmacol 1992; 107: 58-65.
24. Randall MD, Griffith TM. Modulation of vasodilation to levrocromakalim by hypoxia and EDRF in the isolated perfused rabbit ear: a comparison with pinacidil, sodium nitroprusside and verapamil. Br J Pharmacol 1993; 109: 386-93.
25. Nielsen-Kudsk J, Bang L, Bronsgraad AM. Glibenclamide blocks the relaxant action of pinacidil and cromakalim in airway smooth muscle. Eur J Pharmacol 1990; 180: 291-6.
26. Berry JL, Elliot KRF, Foster RW, Green KA, Murray MA, Small RC. Mechanical, biochemical and electrophysiological studies of RP 49356 and cromakalim in guinea-pig trachealis muscle. Pulm Pharmacol 1991; 4: 91-8.
27. Lawson K. Potassium channel activation: a potential therapeutic approach? Pharmacol Ther 1996; 70: 39-63.
28. ATP - fact or artefact? New thoughts on the mode of action of the potassium channel openers. Cardiovasc Res 1994; 28: 735-7.
29. Chopra LC, Twort CHC, Ward JPT. Direct action of BRL 38227 and glibenclamide on intracellular calcium stores in cultured airway smooth muscle of rabbit. Br J Pharmacol 1992; 105: 259-60.
30. 2+ concentration and mechanical activity induced by noradrenaline in the rabbit mesenteric artery. Br J Pharmacol 1991; 104: 227-33.
31. Yamagishi T, Yanigasawa T, Taira N. K channel openers, cromakalim and Ki4032, inhibit agonist-induced Ca release in canine coronary artery. Naunyn-Schmeideberg's Arch Pharmacol 1992; 346: 691-700.
32. Coldwell MC, Hewlett DR. Specificity of action of the novel antihypertensive agent, BRL 34915, as a potassium channel activator. Comparison with nicorandil. Biochem Pharmacol 1987; 36: 3663-9.
33. Okada Y, Yanigasawa T, Taira N. BRL 38227 (lemakalim)-induced hyperpolarization reduces the sensitivity to Ca of contractile elements in canine coronary artery. Naunyn-Schmeideberg's Arch Pharmacol 1993; 347: 438-44.
34. Greenwood IA, Weston AH. Effects of rubidium on responses to potassium channel openers in rat isolated aorta. Br J Pharmacol 1993; 109: 925-32.
35. Senior R, Buchnermoell D, Raftery E, Lahiri A. Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans. J Cardiovasc Pharmacol 1993; 22: 717-21.
36. Grover GJ. Protective effects of ATP-sensitive potassium channel openers in experimental myocardial ischemia. J Cardiovasc Pharmacol 1994; 24: S18-27.
37. Coetzee WA. ATP-sensitive potassium channels and myocardial ischemia: why do they open? Cardiovasc Drugs Ther 1992; 6: 201-8.
38. Tsutamoto T, Kinoshita M, Nakee I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994; 127: 866-73.
39. Knight C, Purcell H, Fox K. Potassium channel openers - clinical applications in ischemic heart disease - overview of clinical efficacy of nicorandil. Cardiovasc Drugs Ther 1995; 9: 229-36.
40. Thomas P, Dixon MS, Winterton SJ, Sheridan DJ. Acute haemodynamic effects of cromakalim in patients with angina pectoris. Br J Clin Pharmacol 1990; 29: 325-31.
41. Ghaleh B, Dubois-Rande JL, Hittinger L, Giudicelli JF, Berdeaux A. Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium. Br J Pharmacol 1995; 114: 496-502.
42. + channels in rat aorta and brain microvascular endothelial cells. Am J Physiol 1993; 265: C812-21.
43. 2x Fundam Clin Pharmacol 1993; 7: 183.
44. Luckhoff A, Busse R. Activators of potassium channels enhance calcium influx into endothelial cells as a consequence of potassium currents. Naunyn-Schmiedeberg's Arch Pharmacol 1990; 342: 94-9.
45. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration and infarct size in dogs. Circulation 1994; 89: 1769-75.
46. Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448. J Cardiovasc Pharmacol 1995; 25: 40-50.
47. Auchampach JA, Maruyama M, Cavero I, Gross GJ. Pharmacological evidence for a role of ATP-dependent potassium channels in myocardial stunning. Circulation 1992; 86: 311-9.
48. Gross GJ, Auchampach JA. Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 1992; 70: 223-33.
49. Gautier P, Bertrand JP, Guiraudou P. Effects of SR-44866, a potassium channel opener, on action potentials of rabbit, guinea-pig and human heart fibers. J Cardiovasc Pharmacol 1991; 17: 692-700.
50. Toombs CF, Norman NR, Groppi VE, Lee KS, Gadwood RC, Shebuski RJ. Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs cardiac actions in vitro and in vivo. J Pharmacol Exp Ther 1992; 263: 1261-8.
51. ATP-openers. J Cardiovasc Pharmacol 1994; 24: S12-17.
52. Black SC, Lucchesi BR. Potassium channel openers are likely to be proarrhythmic in the diseased human heart. Cardiovasc Res 1994; 28: 923-4.
53. Wilde AAM. Proarrhythmic potential of the potassium channel openers. Cardiovasc Res 1994; 28: 928-9.
54. Haverkamp W, Borggrefe M, Breithardt G. Electrophysiologic effects of potassium channel openers. Cardiovasc Drugs Ther 1995; 9: 195-202.
55. Antzelevitch C, Di Diego JM. Role of K channel activators in cardiac electrophysiology and arrhythmias. Circulation 1992; 85: 1627-9.
56. Carlsson L, Abrahamsson C, Drews L, Duker G. Anti-arrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization. Circulation 1991; 85: 1491-500.
57. Cook NS, Chapman ID. Therapeutic potential of potassium channel openers in peripheral vascular disease and asthma. Cardiovasc Drugs Ther 1993; 7: 555-63.
58. 2+ antagonists or hydralazine, in an animal model of occlusive arterial disease. Naunyn-Schmiedeberg's Arch Pharmacol 1988; 337: 341-6.
59. + channel openers. In: Frohlich JC, Fostermann U, eds. Importance of prostacyclin and potassium channels for the regulation of vascular tone. Munich: Zuckschwerdt, 1990: 128-36.
60. Tulenko TN, Bialecki R. Altered potassium channel ion fluxes to vasoactive stimuli following cholesterol enrichment in arterial smooth muscle. Arteriosclerosis 1989; 9: 769.
61. Patelunas-Hoffman DM, Carmint WJ, Colatsky TJ, Fenichel RL. Analysis of the potassium channel openers celikalim, pinacidil and cromakalim in platelet models of thrombosis. Thromb Res 1994; 74: 441-52.
62. Arch JRS, Bowring NE, Buckle DR. Evaluation of the novel potassium channel activator BRL 55834 as an inhaled bronchodilator in guinea-pig and rats - comparison with levrocromakalim and salbutamol. Pulm Pharmacol 1994; 7: 121-8.
63. Edwards G, Schneider J, Niederste-Hollenberg A, Noack Th, Weston AH. Effects of BRL 55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide-resistant, ATP-sensitive potassium channel. Br J Pharmacol 1995; 115: 1027-37.
64. Taylor SG, Arch JRS, Bond J, et al. The inhibitory effects of cromakalim and its active enantiomer BRL 38227 against various spasmogens in guinea-pig and human airways: comparison with pinacidil and verapamil. J Pharmacol Exp Ther 1992; 261: 429-37.
65. Martin CAE, Naline E, Advenier C. Action of a novel potassium channel opener SR-47063 on human bronchi and on guinea-pig trachea in vitro - a comparison with cromakalim. Drug Dev Res 1993; 29: 63-72.
66. Imagawa J, Yoshida S, Koga T, Kamei K, Nabata H. The effect of a novel benzopyran derivative KC 399 on the isolated guinea-pig trachealis and human bronchi. Gen Pharmacol 1993; 24: 1505-12.
67. Chapman ID, Kristersson A, Mathelin G, et al. Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol 1992; 106: 423-9.
68. + channel openers and suppression of airway hyperactivity. Trends Pharmacol Sci 1994; 15: 463-8.
69. Smith H. Asthma, inflammation, eosinophils and bronchial hyperresponsiveness. Clin Exp Allergy 1992; 22: 187-97.
70. Burka JF, Berry JL, Foster RW, Small RC, Watt AJ. Effects of cromakalim on neurally-mediated responses of guinea-pig tracheal smooth muscle. Br J Pharmacol 1991; 104: 263-9.
71. 3H] acetylcholine release from a tube preparation of the rat isolated trachea by an epithelium dependent mechanism. Naunyn-Schmeideberg's Arch Pharmacol 1993; 348: 14-20.
72. + channel activator, BRL-38227, in guinea-pig airways in vivo. Eur J Pharmacol 1993; 239: 257-9.
73. Ishikawa J, Ichinose M, Nakajima N, et al. Potassium channel opener, YM-934, inhibits neurogenic plasma leakage in guinea-pig airways. Am J Respir Crit Care Med 1994; 150: 1379-83.
74. Williams AJ, Lee TH, Cochrane GM, et al. Attenuation of nocturnal asthma by cromakalim. Lancet 1990; 336: 334-6.
75. Villanove X, Marthan R, Delara JMT, et al. Sensitization decreases relaxation in human isolated airways. Am Rev Respir Dis 1993; 148: 107-12.
76. Kidney JC, Fuller RW, Worsdell YM, Lavender EA, Chung KF, Barnes PJ. Effect of an oral potassium channel activator, BRL 38227, on airway function and responsiveness in asthmatic patients - comparison with oral salbutamol. Thorax 1993; 48: 130-3.
77. Fauschou P, Mikkelsen KL, Steffensen I, Franke B. The lack of bronchodilator effect and the short-term safety of cumulative single doses of an inhaled potassium channel opener (bimakalim) in adult patients with mild-to-moderate bronchial asthma. Pulm Pharmacol 1994; 7: 293-7.
78. Morrison JJ, Ashford ML, Khan RN, Smith SK. Effects of PCOs on isolated pregnant human myometrium before and after the onset of labor: potential of tocolysis. Am J Obstet Gynecol 1993; 169: 1277-85.
79. Monga M, Creasy RK. Management of preterm labor. Semin Perinatol 1995; 19: 84-96.
80. Piper I, Downing SJ, Hollingsworth M. Cross tolerance between cromakalim and RP 49356 in the uterus of the rat in vivo and in vitro. Eur J Pharmacol 1992; 219: 347-53.
81. Cheuk JMS, Hollingworth M, Hughes SJ, Piper IT, Maresh MJA. Inhibition of contraction of the isolated human myometrium by potassium channel openers. Am J Obstet Gynecol 1993; 168: 953-60.
82. + on the responses to levcromakalim and P1060 in the isolated human myometrium. Eur J Pharmacol 1995; 272: 293-6.
83. Holmquist F, Andersson K-E, Hedlund H. Effects of pinacidil on isolated human corpus cavernosum penis. Acta Physiol Scand 1990; 138: 463-9.
84. Trigo-Rocha F, Hsu GL, Donatucci CF, Martinez-Pineiro L, Lue TF, Tanagho EA. Intracellular mechanism of penile erection in monkeys. Neurourol-Urodyn 1994; 13: 71-80.
85. Radomski SB, Herschorn S, Rangaswamy S. Topical minoxidil in the treatment of male erectile dysfunction. J Urol 1994; 151: 1225-6.
86. Chancellor MB, Rivas DA, Panzer DE, Freedman MK, Staas WE. Prospective comparison of topical minoxidil to vacuum constriction device and intracorporeal papaverine injection in treatment of erectile dysfunction due to spinal-cord injury. Urology 1994; 43: 365-9.
87. Edwards G, Henshaw M, Miller M, Weston AH. Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro. Br J Pharmacol 1991; 102: 679-86.
88. + channel openers. Trends Pharmacol Sci 1994; 15: 402-4.
89. Hedlung H, Mattiasson A, Andersson K-E. Effects of pinacidil on detrusor instability in men with bladder outlet obstruction. J Urol 1991; 146: 1345-7.
90. Komersova K, Rogerson JW, Conway EL, et al. The effects of levrocromakalim (BRL 38227) on bladder function in patients with high spinal-cord lesion. Br J Clin Pharmacol 1995; 39: 207-9.
91. Poggioli R, Benelli A, Arletti R, Cavazzuti E, Bertolini A. Potassium channel openers delay intestinal transit and have antidiarrheal activity. Eur J Pharmacol 1995; 287: 207-9.
92. 125I] iodoglyburide in the rat brain. Neuroscience 1993; 52: 191-205.
93. Zini S, Roisin AAP, Armengaud C, Ben-Ari Y. Effect of potassium channel modulators on the release of glutamate induced by ischaemic-like conditions in rat hippocampal slices. Neurosci Lett 1993; 153: 202-5.
94. + channel openers prevent global ischaemia-induced expression of c-fos, c-jun, heat-shock protein and amyloid beta-protein precursor genes and neuronal death in rat hippocampus. Proc Natl Acad Sci U.S.A. 1993; 90: 9431-5.
95. + channel openers protect hippocampal neurons against oxidative injury and amyloid β-peptide toxicity. Brain Res 1996; 706: 328-32.
96. + channels and block neurosecretion. Proc Natl Acad Sci U.S.A. 1990; 87: 3489-92.
97. + channel openers decrease seizures in genetically epileptic rats. Eur J Pharmacol 1989; 167: 181-3.
98. Popoli P, Pezzola A, Sagratella S, Zeng YC, Scotti de Carolis A. Cromakalim (BRL 34915) counteracts the epileptiform activity elicited by diltiazem and verapamil in rats. Br J Pharmacol 1991; 104: 907-13.
99. Mclean MJ, Schmutz M, Wamil AW, Olpe HR, Portet C, Feldmann KF. Oxcarbazepine - mechanism of action. Epilepsia 1994; 35: S5-9.
100. Ocana M, Del Pozo E, Baeyens JM. ATP dependent K channel blockers antagonise morphine but not U-504,884-induced antinodception. Eur J Pharmacol 1993; 230: 203-7.
101. Welch SP, Dunlow LD. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists: a common mechanism of action? J Pharmacol Exp Ther 1993; 267: 390-9.
102. Vergoni AV, Scarano A, Bertonini A. Pinacidil potentiates morphine analgesia. Life Sci 1992; 50: 135-8.
103. Rang HP, Urban L. New molecules in analgesia. Br J Anaesth 1995; 75: 145-56.
104. Garcia G, Malta A, Soubrie P. European patent application, EP370 901A. 1990.
105. Poucelet M. European patent application, EP 370902. 1990.
106. + channels in the rat dorsal pallidum. Eur J Pharmacol 1992; 217: 71-7.
107. Clissold SP, Heel RC. Topical minoxodil. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in alopecia areata and alopecia androgenetica. Drugs 1987; 33: 107-22.
108. Waldon DJ, Kawabe TT, Barker CA, Johnson GA, Buhl AE. Enhanced in vitro hair growth at the air liquid interface: minoxidil preserves the root sheath in cultured whisker follicles. InVitro Cell Dev Biol 1993; 29A: 555-61.
109. Harmon CS, Lutz D, Ducote J. Potassium channel openers stimulate DNA synthesis in mouse epidermal keratinocyte and whole hair follicle cultures. Skin Pharmacol 1993; 6: 170-8.
110. Godtfredsen WO. New ophthalmic preparation for treating glaucoma. World patent application, WO 89/10757. 1989.
111. Millar C, Wilson WS. Comparison of the effects of vasodilator drugs on intraocular pressure and vascular relaxation. Br J Pharmacol 1991; 104: 55P.